StreetInsider.com News Articles

Form 4 AtaiBeckley Inc. For: Mar 11 Filed by: Faerm Michael E.

Fri, 13 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260313/26160427.html

Form 4 AtaiBeckley Inc. For: Mar 11 Filed by: Faerm Michael E.

Fri, 13 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260313/26160427.html

Form 3 AtaiBeckley Inc. For: Mar 09 Filed by: Faerm Michael E.

Fri, 13 Mar 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260313/26160407.html

Form 3 AtaiBeckley Inc. For: Mar 09 Filed by: Faerm Michael E.

Fri, 13 Mar 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260313/26160407.html

H.C. Wainwright Reiterates Buy Rating on atai Life Sciences N.V (ATAI)

Tue, 10 Mar 2026 07:23:01 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $25.00 price target on atai Life Sciences N.V (NASDAQ: ATAI).

The analyst commented: "On March 6, AtaiBeckley held a virtual investor day, an event that served as a comprehensive deep-dive into AtaiBeckley's lead asset, BPL-003 (mebufotenin benzoate). The central development was the unveiling of the ReConnection Phase 3 pivotal program architecture, which consists of two complementary trials ReConnection-1 and ReConnection-2 set for initiation in 2Q26 with topline data anticipated in early 2029. ReConnection-1 (n≈350), is a 2:1:2 randomized trial (8mg vs. 4mg vs. placebo) evaluating a single-dose induction strategy, while ReConnection-2

AtaiBeckley plans phase 3 trials for depression drug in Q2 2026

Tue, 10 Mar 2026 06:00:14 -0400

AtaiBeckley Inc. (NASDAQ: ATAI) announced plans to initiate two parallel Phase 3 studies for BPL-003, a nasal spray treatment for treatment-resistant depression, in the second quarter of 2026 following a successful End-of-Phase 2 meeting with the FDA.

The biotechnology company outlined the timeline during its 2026 Virtual Investor Day. BPL-003, which holds FDA Breakthrough Therapy Designation, demonstrated rapid antidepressant effects at Day 2, with durable improvements maintained through eight weeks in Phase 2b trials.

The two pivotal trials, named ReConnection-1 and ReConnection-2, will include a 12-week randomized, double-blind, placebo-controlled core study, followed by a 52-week open-label extension allowing individualized retreatment based on

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

Tue, 10 Mar 2026 06:00:00 -0400

BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression
Cash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studies
Commercial readiness advancing with scalable treatment model aligned to existing interventional psychiatry workflows
Continued pipeline progress, including positive Phase 2a results for EMP‑01 and expected Phase 2 topline for VLS-01 in H2 2026
Replay and presentation materials available on AtaiBeckley’s investor website

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

Tue, 10 Mar 2026 06:00:00 -0400

BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression
Cash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studies
Commercial readiness advancing with scalable treatment model aligned to existing interventional psychiatry workflows
Continued pipeline progress, including positive Phase 2a results for EMP‑01 and expected Phase 2 topline for VLS-01 in H2 2026
Replay and presentation materials available on AtaiBeckley’s investor website

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on

AtaiBeckley (ATAI) files mixed shelf

Mon, 09 Mar 2026 06:04:51 -0400

AtaiBeckley (NASDAQ: ATAI) has filed mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units

AtaiBeckley (ATAI) files mixed shelf

Mon, 09 Mar 2026 06:04:51 -0400

AtaiBeckley (NASDAQ: ATAI) has filed mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units

AtaiBeckley (ATAI) files mixed shelf

Mon, 09 Mar 2026 06:04:51 -0400

AtaiBeckley (NASDAQ: ATAI) has filed mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units

Jefferies Reiterates Buy Rating on atai Life Sciences N.V (ATAI): "keen on ATAI's robust BPL-003 Phase IIb TRD results"

Fri, 06 Mar 2026 15:37:13 -0400

Jefferies analyst Andrew Tsai reiterated a Buy rating and $10.00 price target on atai Life Sciences N.V (NASDAQ: ATAI)

The analyst commented, "For ATAI's $1B+ psychedelic programs: (1) In Q2:26, BPL-003 (intranasal 5- MeO-DMT) will start two Phase IIIs in TRD depression. Our 70-75%+ confidence is attributed to Phase IIb results confirming '003 can safely produce rapid, meaningful, and durable efficacy. (2) In H2:26, VLS-01 (buccal film DMT) has Phase II TRD data (+25-50% stock move), (3) Awaiting next steps for EMP-01 (oral R-MDMA) after showing supportive Phase IIa efficacy in social anxiety (SAD). Big Picture: BPL-003, which received a BTD

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Fri, 06 Mar 2026 07:00:00 -0400

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration
On-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026
Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measures
Cash runway through the planned early-2029 topline readouts from both Phase 3 pivotal studies
Virtual Investor Day scheduled for March 6, 2026

NEW YORK, March 06,

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Fri, 06 Mar 2026 07:00:00 -0400

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration
On-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026
Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measures
Cash runway through the planned early-2029 topline readouts from both Phase 3 pivotal studies
Virtual Investor Day scheduled for March 6, 2026

NEW YORK, March 06,

AtaiBeckley receives FDA support for BPL-003 Phase 3 depression program

Tue, 03 Mar 2026 07:00:55 -0400

AtaiBeckley Inc. (NASDAQ: ATAI) announced the Food and Drug Administration has indicated support for the company's proposed Phase 3 program for BPL-003, an intranasal formulation being developed for treatment-resistant depression.

The biotechnology company reported a successful End-of-Phase 2 meeting with the FDA, with meeting minutes showing the agency provided constructive feedback on the overall design and key components of the proposed program. The FDA also addressed the overall size of the safety database required for this chronic indication.

BPL-003 previously received Breakthrough Therapy designation from the FDA in October 2025 for treatment-resistant depression. The company maintains its timeline for Phase 3 program

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

Tue, 03 Mar 2026 07:00:00 -0400

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosing
Phase 3 program initiation remains on track for Q2 2026
BPL-003 was previously granted Breakthrough Therapy designation by the FDA for treatment-resistant depression
Virtual Investor Day scheduled on March 6, 2026, to provide further detail on the BPL-003 Phase 3 clinical strategy

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

Tue, 03 Mar 2026 07:00:00 -0400

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosing
Phase 3 program initiation remains on track for Q2 2026
BPL-003 was previously granted Breakthrough Therapy designation by the FDA for treatment-resistant depression
Virtual Investor Day scheduled on March 6, 2026, to provide further detail on the BPL-003 Phase 3 clinical strategy

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient

Form 144 Atai Beckley N.V. Filed by: Feilding-Mellen Cosmo

Thu, 26 Feb 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260226/26070955.html

Form 144 Atai Beckley N.V. Filed by: Feilding-Mellen Cosmo

Thu, 26 Feb 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260226/26070955.html

AtaiBeckley reports positive trial results for social anxiety drug

Thu, 26 Feb 2026 07:00:20 -0400

AtaiBeckley Inc. (NASDAQ: ATAI) announced positive results from a Phase 2a trial of EMP-01, an oral R-MDMA treatment for social anxiety disorder. The study met its primary safety objective and showed efficacy signals in 71 adults with moderate-to-severe social anxiety disorder across seven clinical sites in the UK.

The trial demonstrated that EMP-01 produced a placebo-adjusted reduction of 11.85 points on the Liebowitz Social Anxiety Scale at Day 43, with a p-value of 0.036. On the Clinician Global Impression-Improvement assessment, 49% of EMP-01 patients showed improvement compared to 15% for placebo, corresponding to a Number Needed to Treat of 2.95.

Participants received

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

Thu, 26 Feb 2026 07:00:00 -0400

EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profile
EMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one-tailed)
EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95
EMP-01 demonstrated improvements across both Fear and Avoidance sub-domains of the LSAS, including improvement in social avoidance behaviors after two administrations over

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

Thu, 26 Feb 2026 07:00:00 -0400

EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profile
EMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one-tailed)
EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95
EMP-01 demonstrated improvements across both Fear and Avoidance sub-domains of the LSAS, including improvement in social avoidance behaviors after two administrations over

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

Fri, 20 Feb 2026 07:00:00 -0400

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company’s executive leadership team and several external key opinion leaders.

Investors, analysts, and members of the media are invited to register for the live webcast. A replay

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

Fri, 20 Feb 2026 07:00:00 -0400

Investors, analysts, and members of the media are invited to register for the live webcast. A replay

AtaiBeckley names Michael Faerm as chief financial officer

Thu, 19 Feb 2026 07:00:28 -0400

AtaiBeckley Inc (NASDAQ: ATAI) announced the appointment of Michael Faerm as chief financial officer, effective March 9, 2026. The clinical-stage biotechnology company focuses on developing mental health treatments.

Faerm brings over 25 years of experience across life sciences companies, equity research, and investment banking. He will lead the company's financial strategy, capital markets activities, and overall financial operations.

Anne Johnson, who has served as chief financial officer since 2024, will transition to chief accounting officer when Faerm's appointment takes effect. Johnson will continue leading accounting and financial operations while working with Faerm to ensure operational continuity.

Faerm most recently served as chief financial